Medicover Integrated Clinical Services Sp. z o.o.

Research site

Poland Ul. Jana Karola Chodkiewicza 19c, 85-065 Bydgoszcz, Poland

18 trials recruiting
Psoriatic arthropathy · Myasthenia gravis · Systemic lupus erythematosus
Adults and children

About Specializations

Medicover Integrated Clinical Services Sp. z o.o. in Bydgoszcz, Poland specialises in clinical trials of conditions such as Psoriatic arthropathy, Myasthenia gravis, Systemic lupus erythematosus, Chronic inflammatory demyelinating polyradiculoneuropathy, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ul. Jana Karola Chodkiewicza 19c85-065 BydgoszczPoland

Open in maps ↗

Recruiting now: 18 trials
Conditions studied: 20

More sites in Bydgoszcz Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

55 clinical trials

Systemic lupus erythematosus

Recruiting

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

Psoriatic arthropathy

Recruiting

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Zasocitinib
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Empasiprubart
Sponsor:Argenx

Contact Research Centre

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Emtricitabine
Sponsor:Novartis Pharma AG

Contact Research Centre

Myasthenia gravis

Recruiting

A Phase 2a Study of Empasiprubart IV Monotherapy in Adults with AChR‑Ab Seropositive Generalized Myasthenia Gravis

Registered drug

A Phase 2a Study of Empasiprubart IV Monotherapy in Adults with AChR‑Ab Seropositive Generalized Myasthenia Gravis

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo

Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Human Normal Immunoglobulin
Sponsor:Grifols Therapeutics LLC

Contact Research Centre

Myasthenia gravis

Recruiting

Phase 2 Randomized Study of Povetacicept to Assess Safety and Effectiveness in Adults with Generalized Myasthenia Gravis

Investigational

Phase 2 Randomized Study of Povetacicept to Assess Safety and Effectiveness in Adults with Generalized Myasthenia Gravis

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Povetacicept
Sponsor:Vertex Pharmaceuticals Inc.

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Nipocalimab
Sponsor:Janssen Cilag International

Contact Research Centre

Psoriatic arthropathy

Recruiting

Tulisokibart for Psoriatic Arthritis in Adults

Investigational

Tulisokibart for Psoriatic Arthritis in Adults

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Tulisokibart
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Myasthenia gravis

Recruiting

A study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites